Evoking neuronal activity to improve the lives of Alzheimer’s patients
.webp)
Cognito's headset design concept
We are leading a novel category of disease-modifying therapy in Alzheimer’s disease
Developed with a novel mechanism of action
Research shows that Alzheimer's patients have abnormal neuronal activity in the brain. We're advancing a new way of treating Alzheimer's disease by targeting this abnormal activity.
.svg)
Promising results from our Phase 2 study
In our Phase 2 OVERTURE trial, significant slowing of disease progression was observed among treated patients through the preservation of cognition, daily function, and whole brain volume. No serious treatment-limiting adverse events were reported.
Designed to fit into patient’s lives
Patients receive this non-invasive treatment from the comfort of their home for one hour each day.
Why do the brain's electrical activities matter?
Neurons communicate through electric signals, creating rhythmic brain activity known as "brain waves." When groups of neurons start firing at the same time, distinct brain waves form at various ranges. One such range is gamma waves, which play an important role in learning and memory. In Alzheimer’s patients, gamma waves are altered, indicating impairment in normal brain function.a
How does our treatment work?
Our novel therapy is designed to evoke gamma wave activity through non-invasive visual and auditory stimulation. In prior clinical studies, it slowed cognitive and functional decline and loss of brain structure among treated Alzheimer's patients.
.webp)
Cognito's headset design concept
Cognito's headset design concept
.webp)
Our treatment received the FDA Breakthrough Device Designation for the treatment of cognitive and functional symptoms associated with Alzheimer’s disease, and we are expanding our approach to many other indications.
.svg)
Click to enlarge
It all started with a breakthrough from leading MIT neuroscientists
Press, publications & announcements
October 30, 2024
Advancing Alzheimer Treatment Through Gamma Oscillation Stimulation: Ralph Kern, MD, MHSc
October 30, 2024
Cognito Therapeutics’ Alzheimer’s treatment reduces dependence score by 56%
.svg)
October 29, 2024
Cognito Therapeutics Announces Spectris™ Treatment Demonstrates 56.4% Reduction in Alzheimer’s Disease Dependence Score with Strong Safety Profile
October 16, 2024
Cognito Therapeutics has positive data for Alzheimer’s-modifying therapy
October 16, 2024
Cognito Therapeutics Publishes Study Demonstrating Structural Brain Preservation in Alzheimer’s Disease in Frontiers in Neurology